摘要
目的探讨小剂量泼尼松联合来氟米特、硫酸羟氯喹治疗类风湿性关节炎患者的临床效果。方法选取沈阳市中医院2018年1月至2019年5月收治的100例类风湿性关节炎患者作为研究对象,随机分为对照组与观察组,各50例。对照组采用大剂量泼尼松进行治疗,观察组采用小剂量泼尼松进行治疗,比较两组的临床治疗效果。结果治疗前,两组患者视觉模拟评分法(VAS)和类风湿关节炎病情活动度评价表(DAS28)评分比较差异无统计学意义(P>0.05);治疗后,两组VAS和DAS28评分明显降低,且观察组VAS和DAS28评分明显低于对照组,差异有统计学意义(P<0.05)。治疗前,两组患者血清红细胞沉降率(ESR)、C反应蛋白(CRP)、类风湿因子(RF)和骨密度T值绝对值比较差异无统计学意义(P>0.05);治疗后,两组血清ESR、CRP、RF和骨密度T值绝对值明显降低,且观察组ESR、CRP、RF和骨密度T值绝对值明显低于对照组,差异有统计学意义(P<0.05)。结论小剂量泼尼松联合来氟米特、硫酸羟氯喹对类风湿性关节炎进行治疗的效果优于大剂量泼尼松联合氟米特、硫酸羟氯喹。
Objective To analyze the therapeutic effect of low dose prednisone combined with flutamide and hydroxychloroquine sulfate on patients with rheumatoid arthritis. Methods One hundred patients with rheumatoid arthritis admitted to Shenyang Hospital of Traditional Chinese Medicine from January 2018 to May 2019 were selected as the reserch objects and were randomly divided into a control group and an observation group, with fifty cases in each group. The control group was treated with high-dose prednisone, and the observation group was treated with low-dose prednisone. The clinical treatment effects of the two groups were compared. Results Before the treatment, there was no significant difference in VAS and DAS28 scores between the two groups(P>0.05);after the treatment, the VAS and DAS28 scores of the two groups were significantly lower than those of the control group, the difference was statistically significant(P<0.05). There was no significant difference in the changes of serum(ESR), C reactive protein(CRP), rheumatoid factor(RF) and bone mineral density T value between the two groups(P>0.05) before treatment;after treatment, the changes of serum(ESR), C reactive protein(CRP), rheumatoid factor(RF) and Bone density T value in the observation group were significantly lower than those in the control group(P<0.05). Conclusion Low dose prednisone combined with flunomide and hydroxychloroquine sulfate is more effective than high dose prednisone combined with flunomide and hydroxychloroquine sulfate in the treatment of rheumatoid arthritis.
作者
潘贤峰
李季
李东书
PAN Xian-Feng;LI Ji;LI Dong-Shu(Shenyang Hospital of Traditional Chinese Medicine,Shenyang 110000,China)
出处
《中国药物经济学》
2020年第10期77-79,共3页
China Journal of Pharmaceutical Economics
